Cholera Vaccines Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Whole cell V. Cholerae O1 Recombinant With B-Subunit and Killed Oral O1 & O139), By Product (Vaxchora, Dukoral, Shanchol, and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Others), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 97.32 MIllion
CAGR (2026-2031)	9.32%
Fastest Growing Segment	Shanchol
Largest Market	Asia Pacific
Market Size (2031)	USD 166.11 MIllion

Market Overview

The Global Cholera Vaccines Market will grow from USD 97.32 MIllion in 2025 to USD 166.11 MIllion by 2031 at a 9.32% CAGR. Global Cholera Vaccines are biological preparations, predominantly oral formulations, administered to induce immunity against the Vibrio cholerae bacterium. The market is primarily propelled by the intensifying frequency of cholera outbreaks attributed to climate change phenomena, such as severe flooding and droughts, which compromise water and sanitation infrastructure. Furthermore, the escalation of humanitarian crises and population displacement has necessitated rigorous mass vaccination campaigns to mitigate morbidity in high-risk zones. According to the International Coordinating Group on Vaccine Provision, in 2025, more than 40 million doses of oral cholera vaccine were allocated globally to address surging outbreaks and humanitarian emergencies.

Despite the robust demand, the market encounters a significant challenge regarding the insufficient global production capacity relative to immediate public health requirements. This disequilibrium has resulted in severe stockpile shortages which force health agencies to adopt dose rationing strategies and delay response times in endemic regions. The persistent gap between manufacturing output and the volume of vaccine requests from international bodies remains the primary restraint hindering broader market expansion and timely disease elimination efforts.

Key Market Drivers

The resurgence of cholera outbreaks in endemic regions has emerged as the primary catalyst driving the urgent expansion of the Global Cholera Vaccines Market. This escalation is heavily influenced by climate change-induced events, such as severe floods and cyclones, which contaminate water sources and accelerate the transmission of Vibrio cholerae. The increasing volume of infection has forced international health bodies to aggressively deplete existing stockpiles, creating an immediate need for rapid replenishment and distribution logistics to contain mortality rates. According to the World Health Organization, August 2025, in the 'Multi-country outbreak of cholera' report, global surveillance systems recorded a cumulative total of 409,222 cholera cases and over 4,700 deaths between January and August alone. This surge underscores the critical dependency on vaccination as a primary containment tool, directly influencing procurement volumes for emergency response.

Simultaneously, advancements in vaccine formulation and the expansion of manufacturing infrastructure are reshaping the market's supply dynamics. Recognizing the persistent deficit, pharmaceutical companies and global alliances have mobilized substantial capital to construct high-capacity production facilities and streamline regulatory approvals for new oral candidates. For instance, according to Bharat Biotech, May 2025, in a press statement regarding the Hillchol vaccine, the company announced the establishment of large-scale facilities capable of producing up to 200 million doses annually to bridge the global supply gap. These industrial expansions are further supported by guaranteed purchase commitments from international agencies; according to EuBiologics Co., Ltd, in 2025, the manufacturer executed a framework under a UNICEF award to supply 72 million doses of oral cholera vaccine to meet international public health demands.

Download Free Sample Report

Key Market Challenges

The insufficient global production capacity relative to immediate public health requirements stands as a critical barrier hindering the growth of the Global Cholera Vaccines Market. This manufacturing bottleneck creates a hard ceiling on market volume, effectively preventing the industry from capitalizing on the robust demand generated by frequent outbreaks. When production lines cannot scale rapidly enough to match procurement orders, the market experiences a forced stagnation where potential revenue is lost due to the physical unavailability of the product. Consequently, this deficit restricts the market's ability to expand its geographical footprint, as stakeholders are compelled to ration existing supplies rather than fulfilling the total addressable market need in endemic regions.

The severity of this supply-demand disequilibrium is highlighted by the intense pressure placed on global stockpiles. According to Gavi, the Vaccine Alliance, in the first quarter of 2025, the International Coordinating Group approved requests for 13.9 million doses to combat surges in eight countries, a volume that rapidly depleted available stock levels. This data demonstrates how production limitations act as a primary restraint, preventing the market from reaching its full operational potential and stalling efforts to stabilize supply chains against the backdrop of rising global requirements.

Key Market Trends

The Growth in Private Travel Market and Prophylactic Vaccination Demand is emerging as a lucrative parallel segment to the humanitarian sector, driven by the resurgence of international tourism to endemic zones. Unlike the low-margin emergency stockpile market, this segment focuses on travelers from high-income countries seeking protection against traveler’s diarrhea and cholera, allowing manufacturers to secure higher price points per dose. This commercial viability is incentivizing companies to ramp up distribution in non-outbreak regions to offset the financial volatility often associated with sporadic emergency procurement orders. The strengthening of this private market is evident in recent financial performance; according to Valneva SE, August 2025, in the 'Half Year 2025 Financial Results', sales of the Dukoral vaccine reached €17.4 million in the first six months of the year, representing a 16.4% growth driven largely by recovering travel volumes.

Simultaneously, the Diversification of Global Manufacturing and Supply Base is shifting production geography to reduce reliance on Asian incumbents and enhance regional health security. International stakeholders are actively funding technology transfers to local manufacturers in Africa to decentralize the supply chain and mitigate the risks associated with centralized production bottlenecks. This localization strategy ensures that high-risk continents possess indigenous end-to-end manufacturing capabilities, thereby reducing lead times during future emergencies. Demonstrating this geographic shift, according to Cape Town ETC, November 2025, in the 'SA’s first fully manufactured oral cholera vaccine enters clinical trials' report, the South African biopharmaceutical company Biovac officially commenced Phase 1 clinical trials for its locally manufactured oral cholera vaccine in October 2025.

Segmental Insights

The Shanchol segment is recognized as the fastest-growing category in the Global Cholera Vaccines Market, primarily driven by its logistical efficiency and suitability for emergency response. Unlike the Dukoral vaccine, Shanchol does not require a buffer solution for administration, which significantly simplifies storage and transport during mass immunization campaigns. This operational advantage is particularly critical for deployment in resource-constrained settings where cold chain infrastructure is limited. Furthermore, its prequalification by the World Health Organization facilitates its procurement for global stockpiles, ensuring consistent demand from international agencies and driving the segment's rapid expansion.

Regional Insights

Asia Pacific holds the leading position in the global cholera vaccines market, driven by high endemic disease rates and substantial manufacturing capacity. The region serves as a primary production hub, with key manufacturers in South Korea and India supplying the majority of the global oral cholera vaccine stockpile. This dominance is supported by the World Health Organization, which prequalifies these facilities to ensure vaccine availability for international emergency response efforts. Furthermore, increasing government focus on immunization programs across developing nations in the region continues to sustain market expansion and production consistency.

Recent Developments

• In November 2024, Valneva reported that sales of its cholera vaccine, Dukoral, increased by 85% in the third quarter compared to the same period in the prior year. The company attributed this significant growth to the resumption of marketing activities and the improved product availability following a successful regulatory inspection of its new manufacturing site in Sweden. This positive performance was driven by strong demand in the private travel market, particularly in Canada, and the fulfillment of replenishment orders. The update highlighted the company's recovery from supply constraints and its continued focus on the traveler vaccine segment.
• In August 2024, Bharat Biotech launched a new oral cholera vaccine, Hillchol, following the successful completion of Phase 3 clinical trials and approval by the national drug regulator. Developed under a license from Hilleman Laboratories, the vaccine was produced using a single-strain formulation that proved non-inferior to existing options. The company announced the establishment of large-scale manufacturing facilities capable of producing up to 200 million doses annually to combat the global deficit. While initially launching in the domestic market, the manufacturer initiated the process to secure World Health Organization prequalification for global supply.
• In April 2024, EuBiologics and the International Vaccine Institute announced that their jointly developed simplified oral cholera vaccine, Euvichol-S, achieved prequalification from the World Health Organization. This regulatory milestone confirmed that the new formulation met global standards for safety, efficacy, and quality, permitting United Nations agencies to procure it for distribution. The simplified manufacturing process for this vaccine was designed to improve production yield by approximately 40% compared to the company’s existing product. This approval was a critical step toward alleviating the severe worldwide supply constraints affecting cholera response efforts.
• In March 2024, the International Vaccine Institute commenced the technology transfer of a simplified oral cholera vaccine to Biological E. Limited, a vaccine manufacturer based in India. Following a licensing agreement established the previous year, the institute began providing the necessary technical information, materials, and know-how to enable production at the company's facilities. This collaboration aimed to create a sustainable, low-cost supply of the vaccine for both domestic use and international markets to address global shortages. The project was supported by funding from the Bill & Melinda Gates Foundation, with full transfer completion targeted for 2025.

Key Market Players

• Valneva SE
• Sanofi S.A.
• Emergent BioSolutions Inc.
• EuBiologics Co., Ltd.
• Shantha Biotechnics Limited
• Hilleman Laboratories Singapore Pte Ltd
• Astellas Pharma Inc.
• Incepta Pharmaceuticals Ltd.
• Bharat Biotech Ltd.
• Takeda Pharmaceutical Company Limited

By Type	By Product	By Distribution Channel	By Region
Whole cell V. Cholerae O1 Recombinant With B-Subunit Killed Oral O1 & O139	Vaxchora Dukoral Shanchol Others	Hospital Pharmacy Retail Pharmacy Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Cholera Vaccines Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Cholera Vaccines Market, By Type:

• Whole cell V. Cholerae O1 Recombinant With B-Subunit
• Killed Oral O1 & O139

• Cholera Vaccines Market, By Product:

• Vaxchora
• Dukoral
• Shanchol
• Others

• Cholera Vaccines Market, By Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Others

• Cholera Vaccines Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE